BACKGROUND: Antibiotics are of limited overall clinical benefit for uncomplicated lower respiratory tract infection (LRTI) but there is uncertainty about their effectiveness for patients with features associated with higher levels of antibiotic prescribing. AIM: To estimate the benefits and harms of antibiotics for acute LRTI among those producing coloured sputum, smokers, those with fever or prior comorbidities, and longer duration of prior illness. DESIGN AND SETTING: Secondary analysis of a randomised controlled trial of antibiotic placebo for acute LRTI in primary care. METHOD: Two thousand and sixty-one adults with acute LRTI, where pneumonia was not suspected clinically, were givenamoxicillin or matching placebo. The duration of symptoms, rated moderately bad or worse (primary outcome), symptom severity on days 2-4 (0-6 scale), and the development of new or worsening symptoms were analysed in pre-specified subgroups of interest. Evidence of differential treatment effectiveness was assessed in prespecified subgroups by interaction terms. RESULTS: No subgroups were identified that were significantly more likely to benefit from antibiotics in terms of symptom duration or the development of new or worsening symptoms. Those with a history of significant comorbidities experienced a significantly greater reduction in symptom severity between days 2 and 4 (interaction term -0.28, P = 0.003; estimated effect of antibiotics among those with a past history -0.28 [95% confidence interval = -0.44 to -0.11], P = 0.001), equivalent to three people in 10 rating symptoms as a slight rather than a moderately bad problem. For subgroups not specified in advance antibiotics provided a modest reduction in symptom severity for non-smokers and for those with short prior illness duration (<7 days), and a modest reduction in symptom duration for those with short prior illness duration. CONCLUSION: There is no clear evidence of clinically meaningful benefit from antibiotics in the studied high-risk groups of patients presenting in general practice with uncomplicated LRTIs where prescribing is highest. Any possible benefit must be balanced against the side-effects and longer-term effects on antibiotic resistance.
RCT Entities:
BACKGROUND: Antibiotics are of limited overall clinical benefit for uncomplicated lower respiratory tract infection (LRTI) but there is uncertainty about their effectiveness for patients with features associated with higher levels of antibiotic prescribing. AIM: To estimate the benefits and harms of antibiotics for acute LRTI among those producing coloured sputum, smokers, those with fever or prior comorbidities, and longer duration of prior illness. DESIGN AND SETTING: Secondary analysis of a randomised controlled trial of antibiotic placebo for acute LRTI in primary care. METHOD: Two thousand and sixty-one adults with acute LRTI, where pneumonia was not suspected clinically, were given amoxicillin or matching placebo. The duration of symptoms, rated moderately bad or worse (primary outcome), symptom severity on days 2-4 (0-6 scale), and the development of new or worsening symptoms were analysed in pre-specified subgroups of interest. Evidence of differential treatment effectiveness was assessed in prespecified subgroups by interaction terms. RESULTS: No subgroups were identified that were significantly more likely to benefit from antibiotics in terms of symptom duration or the development of new or worsening symptoms. Those with a history of significant comorbidities experienced a significantly greater reduction in symptom severity between days 2 and 4 (interaction term -0.28, P = 0.003; estimated effect of antibiotics among those with a past history -0.28 [95% confidence interval = -0.44 to -0.11], P = 0.001), equivalent to three people in 10 rating symptoms as a slight rather than a moderately bad problem. For subgroups not specified in advance antibiotics provided a modest reduction in symptom severity for non-smokers and for those with short prior illness duration (<7 days), and a modest reduction in symptom duration for those with short prior illness duration. CONCLUSION: There is no clear evidence of clinically meaningful benefit from antibiotics in the studied high-risk groups of patients presenting in general practice with uncomplicated LRTIs where prescribing is highest. Any possible benefit must be balanced against the side-effects and longer-term effects on antibiotic resistance.
Entities:
Keywords:
antibiotics; primary health care; randomised controlled trial; respiratory infections
Authors: Christopher C Butler; Kerenza Hood; Mark J Kelly; Herman Goossens; Theo Verheij; Paul Little; Hasse Melbye; Antoni Torres; Sigvard Mölstad; Maciek Godycki-Cwirko; Jordi Almirall; Francesco Blasi; Tom Schaberg; Peter Edwards; Ulla-Maija Rautakorpi; Helena Hupkova; Joseph Wood; Jacqui Nuttall; Samuel Coenen Journal: J Antimicrob Chemother Date: 2010-09-18 Impact factor: 5.790
Authors: Giles Greene; Kerenza Hood; Paul Little; Theo Verheij; Herman Goossens; Samuel Coenen; Christopher C Butler Journal: Prim Care Respir J Date: 2011-09
Authors: Paul Little; Kate Rumsby; Joanne Kelly; Louise Watson; Michael Moore; Gregory Warner; Tom Fahey; Ian Williamson Journal: JAMA Date: 2005-06-22 Impact factor: 56.272
Authors: Samuel Coenen; Barbara Michiels; Paul Van Royen; Jean-Claude Van der Auwera; Joke Denekens Journal: BMC Fam Pract Date: 2002-09-09 Impact factor: 2.497
Authors: Robin Bruyndonckx; Niel Hens; Theo Jm Verheij; Marc Aerts; Margareta Ieven; Christopher C Butler; Paul Little; Herman Goossens; Samuel Coenen Journal: Br J Gen Pract Date: 2018-04-09 Impact factor: 5.386
Authors: Michael Moore; Beth Stuart; Paul Little; Sue Smith; Matthew J Thompson; Kyle Knox; Anne van den Bruel; Mark Lown; David Mant Journal: Eur Respir J Date: 2017-11-22 Impact factor: 16.671
Authors: Paul Little; Beth Stuart; Sue Smith; Matthew J Thompson; Kyle Knox; Ann van den Bruel; Mark Lown; Michael Moore; David Mant Journal: BMJ Date: 2017-05-22
Authors: Laura Shallcross; Nick Beckley; Greta Rait; Andrew Hayward; Irene Petersen Journal: J Antimicrob Chemother Date: 2017-06-01 Impact factor: 5.790
Authors: Meera Tandan; Akke Vellinga; Robin Bruyndonckx; Paul Little; Theo Verheij; Chris C Butler; Herman Goossens; Samuel Coenen Journal: Antibiotics (Basel) Date: 2017-12-13
Authors: Matthew Johnson; Liz Cross; Nick Sandison; Jamie Stevenson; Thomas Monks; Michael Moore Journal: BMJ Open Date: 2018-10-25 Impact factor: 2.692